Robert J Wechsler-Reya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5967248/publications.pdf

Version: 2024-02-01

99 papers	10,944 citations	87723 38 h-index	66788 78 g-index
111 all docs	111 docs citations	111 times ranked	13649 citing authors

#	Article	IF	Citations
1	Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. Neuro-Oncology, 2022, 24, 273-286.	0.6	52
2	Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures. Biomaterials, 2022, 280, 121276.	5.7	5
3	Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Science Translational Medicine, 2022, 14, eabf3917.	5.8	13
4	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	5.7	21
5	Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets. Frontiers in Immunology, 2022, 13, 837013.	2.2	1
6	Disruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development. Cell Death and Differentiation, 2022, 29, 1596-1610.	5.0	7
7	DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma. Neuro-Oncology, 2022, 24, i21-i21.	0.6	0
8	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	0.6	0
9	MEDB-66. Investigating intra-tumoral heterogeneity of extrachromosomal DNA in SHH medulloblastoma. Neuro-Oncology, 2022, 24, i121-i122.	0.6	0
10	MEDB-33. The landscape of ecDNA in medulloblastoma. Neuro-Oncology, 2022, 24, i112-i112.	0.6	0
11	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Communications Biology, 2022, 5, .	2.0	8
12	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro-Oncology, 2021, 23, 226-239.	0.6	22
13	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab002.	0.4	2
14	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 2021, 13, .	5.8	26
15	Structure-based virtual screening identifies an 8-hydroxyquinoline as a small molecule GLI1 inhibitor. Molecular Therapy - Oncolytics, 2021, 20, 265-276.	2.0	10
16	Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth. Communications Biology, 2021, 4, 552.	2.0	5
17	OMIC-01. THE LANDSCAPE OF EXTRACHROMOSOMAL CIRCULAR DNA IN MEDULLOBLASTOMA SUBGROUPS. Neuro-Oncology, 2021, 23, i37-i37.	0.6	0
18	EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i11-i12.	0.6	0

#	Article	IF	Citations
19	A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML. Blood, 2021, 137, 3403-3415.	0.6	8
20	OMIC-05. PHOSPHOPROTEOMIC ANALYSIS IDENTIFIES SUBGROUP ENRICHED PATHWAYS AND KINASE SIGNATURES IN MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i37-i38.	0.6	0
21	KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2021, 20, 2035-2048.	1.9	10
22	The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas. Neuro-Oncology, 2021, 23, 572-585.	0.6	23
23	TMOD-25. LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RELAPSE. Neuro-Oncology, 2021, 23, vi220-vi221.	0.6	0
24	BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2021, 23, vi15-vi16.	0.6	0
25	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.4	38
26	NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma. Cell Reports, 2020, 31, 107782.	2.9	35
27	Characterization of G-CSF receptor expression in medulloblastoma. Neuro-Oncology Advances, 2020, 2, vdaa062.	0.4	6
28	Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin Î±vÎ²5 Axis. Cell Stem Cell, 2020, 26, 187-204.e10.	5.2	126
29	MBRS-12. A TRANSPOSON MUTAGENESIS SCREEN IDENTIFIES Rreb1 AS A DRIVER FOR GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii400-iii400.	0.6	0
30	EPEN-04. ONCOGENIC 3D TUMOR GENOME ORGANIZATION IDENTIFIES NEW THERAPEUTIC TARGETS IN EPENDYMOMA. Neuro-Oncology, 2020, 22, iii308-iii308.	0.6	0
31	MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii399-iii399.	0.6	0
32	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2020, 22, iii400-iii400.	0.6	0
33	DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii285-iii285.	0.6	0
34	Predicting Kinase-Substrate Interactions in Medulloblastoma Subtypes. , 2020, , .		0
35	EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY. Neuro-Oncology, 2020, 22, ii103-ii103.	0.6	2
36	TMOD-30. IDENTIFYING NEW DRIVERS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, ii234-ii234.	0.6	0

#	Article	IF	Citations
37	IMMU-48. CD4+ T CELLS RESTRICT MEDULLOBLASTOMA GROWTH AND DISSEMINATION. Neuro-Oncology, 2020, 22, ii115-ii115.	0.6	0
38	TMOD-07. HUMAN DIFFUSE MIDLINE GLIOMA AVATARS AS A PLATFORM TO SEARCH FOR NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 2020, 22, ii229-ii229.	0.6	0
39	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	13.7	273
40	MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii112-ii113.	0.6	0
41	Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. PLoS ONE, 2019, 14, e0214901.	1.1	4
42	Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. Cancer Research, 2019, 79, 905-917.	0.4	33
43	Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. Nature Communications, 2019, 10, 332.	5.8	55
44	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii93-ii93.	0.6	1
45	Structureâ€“Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 3873-3885.	2.9	8
46	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.4	15
47	MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2019, 21, ii108-ii109.	0.6	0
48	Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. Cell Stem Cell, 2019, 25, 855-870.e11.	5.2	38
49	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	13.7	129
50	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling. European Journal of Medicinal Chemistry, 2019, 162, 495-506.	2.6	8
51	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. European Journal of Medicinal Chemistry, 2019, 163, 320-332.	2.6	12
52	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell, 2018, 172, 1050-1062.e14.	13.5	85
53	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. Annual Review of Neuroscience, 2018, 41, 207-232.	5.0	85
54	N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. Nature Neuroscience, 2018, 21, 195-206.	7.1	317

#	Article	IF	Citations
55	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. Cancer Cell, 2018, 33, 435-449.e6.	7.7	52
56	MBRS-14. REGULATION OF MEDULLOBLASTOMA IMMUNOGENICITY BY TP53 AND TNF ALPHA. Neuro-Oncology, 2018, 20, i131-i131.	0.6	0
57	MBRS-65. CHEMI-GENOMIC ANALYSIS OF PATIENT-DERIVED XENOGRAFTS TO IDENTIFY PERSONALIZED THERAPIES FOR MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i142-i142.	0.6	0
58	TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?. Neuro-Oncology, 2018, 20, vi276-vi276.	0.6	0
59	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications, 2018, 9, 4121.	5.8	36
60	PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH. Neuro-Oncology, 2018, 20, i155-i155.	0.6	0
61	Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling, 2018, 11, .	1.6	59
62	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	7.7	406
63	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature, 2017, 543, 122-125.	13.7	530
64	Optical barcoding of PLGA for multispectral analysis of nanoparticle fate in vivo. Journal of Controlled Release, 2017, 253, 172-182.	4.8	28
65	Molecular mechanisms and therapeutic targets in pediatric brain tumors. Science Signaling, 2017, 10, .	1.6	53
66	Brain Tumor Stem Cells Remain in Play. Journal of Clinical Oncology, 2017, 35, 2428-2431.	0.8	54
67	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. Journal of Medicinal Chemistry, 2016, 59, 3635-3649.	2.9	51
68	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266
69	Sonic Hedgehog promotes proliferation of Notch-dependent monociliated choroid plexus tumourÂcells. Nature Cell Biology, 2016, 18, 418-430.	4.6	59
70	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma. Cancer Cell, 2016, 29, 311-323.	7.7	204
71	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research, 2016, 22, 582-595.	3.2	88
72	Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Research, 2015, 75, 5176-5186.	0.4	14

#	Article	IF	Citations
73	Proteomic profiling of high risk medulloblastoma reveals functional biology. Oncotarget, 2015, 6, 14584-14595.	0.8	20
74	Lgr5 Marks Post-Mitotic, Lineage Restricted Cerebellar Granule Neurons during Postnatal Development. PLoS ONE, 2014, 9, e114433.	1.1	14
75	For pediatric glioma, leave no histone unturned. Science, 2014, 346, 1458-1459.	6.0	9
76	SnapShot: Medulloblastoma. Cancer Cell, 2014, 26, 940-940.e1.	7.7	24
77	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
78	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	13.7	378
79	BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	3.2	296
80	The G protein Î± subunit GÎ±s is a tumor suppressor in Sonic hedgehogâ˜driven medulloblastoma. Nature Medicine, 2014, 20, 1035-1042.	15.2	110
81	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	0.8	263
82	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520
83	The role of stem cells and progenitors in the genesis of medulloblastoma. Experimental Neurology, 2014, 260, 69-73.	2.0	30
84	A population of Nestin-expressing progenitors in the cerebellum exhibits increased tumorigenicity. Nature Neuroscience, 2013, 16, 1737-1744.	7.1	100
85	Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. Cancer Research, 2013, 73, 6310-6322.	0.4	52
86	WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development (Cambridge), 2012, 139, 1724-1733.	1.2	115
87	CXCR4 Activation Defines a New Subgroup of Sonic Hedgehogâ€“Driven Medulloblastoma. Cancer Research, 2012, 72, 122-132.	0.4	58
88	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
89	An Animal Model of MYC-Driven Medulloblastoma. Cancer Cell, 2012, 21, 155-167.	7.7	267
90	Subtypes of medulloblastoma have distinct developmental origins. Nature, 2010, 468, 1095-1099.	13.7	710

#	Article	IF	Citations
91	N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes and Development, 2009, 23, 157-170.	2.7	57
92	Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem Cells. Cancer Cell, 2008, 14, 135-145.	7.7	606
93	Isolation of neural stem cells from the postnatal cerebellum. Nature Neuroscience, 2005, 8, 723-729.	7.1	435
94	Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development (Cambridge), 2005, 132, 2425-2439.	1.2	223
95	Analysis of Gene Expression in the Normal and Malignant Cerebellum. Endocrine Reviews, 2003, 58, 227-248.	7.1	23
96	The Developmental Biology of Brain Tumors. Annual Review of Neuroscience, 2001, 24, 385-428.	5.0	446
97	Evidence that haploinsufficiency ofPtch leads to medulloblastoma in mice. Genes Chromosomes and Cancer, 2000, 28, 77-81.	1.5	136
98	Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. , 2000, 28, 77.		2
99	Control of Neuronal Precursor Proliferation in the Cerebellum by Sonic Hedgehog. Neuron, 1999, 22, 103-114.	3.8	1,228